Our partner is privately held biotech company providing a novel biomarker solution to personalize drug development. Their industry leading technology platform enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Their platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

This highly influential hire utilized the established numerous strategic collaborations to increase our partner’s pipeline of assets, explored new treatment areas, and advanced oncology programs to broaden the patient populations they served. They oversaw all global Clinical programs, developed innovative clinical development plans that drove early decision making based on objective clinical safety and efficacy response measures, and represented the team regarding clinical development, safety concerns, ADEs, clinical trial results, and the drug development pipeline.